Boston Scientific’s Ingenio Pacemaker Wins U.S. FDA Approval

Boston Scientific Corp.’s Ingenio and Advantio pacemakers won U.S. approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade in the $4 billion global market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.